A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease.

Objective Braak’s hypothesis states that Parkinson’s disease (PD) originates in the gastrointestinal (GI) tract, and similar associations have been established for Alzheimer’s disease (AD) and ...

Adjustments to dopaminergic therapy can resolve camptocormia in some patients, as demonstrated in the present case, but such a robust response to antiparkinsonian medications alone is generally ...

Involuntary movements — or dyskinesias — are a debilitating complication of levodopa therapy for Parkinson's disease that is experienced by most patients. Despite the importance of this ...